Commure stock $46.04 USD
Private-market facts for current and former Commure employees researching their stock.
Price per share sourced from public secondary-market data. Updated April 2026. Indicative only — not a live quote.
Overview
Commure provides AI-powered operating system infrastructure for healthcare, connecting EHR systems and clinical workflows to automate documentation, reduce administrative burden, and improve care delivery.
Commure outlook
For employees evaluating Commure equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Commure shares
Why shareholders consider selling
Shareholders in Commure may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Commure does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Commure stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Commure shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Commure shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series E round, its reported $4B valuation and recent secondary-market pricing can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Commure shareholders
Exploring equity in Commure often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Commure most recently raised a Series E round in June 2024. The company was valued at $4B. Total funding raised to date is approximately $400M.
Lead investors in this round include General Catalyst and Andreessen Horowitz.
Founders & company background
Commure was founded in 2017 by Tanay Tandon and is headquartered in San Francisco, CA.
Investors
Industry
Similar private companies
Latest Commure news
Frequently asked questions
- Is Commure still a private company?
- Yes, Commure is currently a private company.
- What is Commure's latest funding round?
- Commure's most recent known round is Series E, raised in June 2024.
- What is Commure's valuation?
- Commure's latest reported valuation is $4B.
- Who are the investors in Commure?
- Notable investors include General Catalyst, Andreessen Horowitz, Greenoaks Capital.
- Can I sell my Commure stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Commure stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Commure data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.